Skip to content
MarketScale
‹ Back to IndustriesHealthcare

New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Clinical AI at a crossroads: skill decay, robotic surgery, and the wearable data frontier

Clinical AI at a crossroads: skill decay, robotic surgery, and the wearable data frontier

The article discusses the impact of three converging developments on the use of AI in healthcare: skill decay, robotic surgery, and wearable data analytics. These advancements are prompting health system operators to reevaluate the deployment and management of AI in clinical environments. The focus is on how AI is integrated, governed, and assessed in healthcare settings.

  • 01Health systems are rethinking AI deployment due to the impact of skill decay, robotic surgery, and wearable data.
  • 02The integration of AI in healthcare requires reevaluation of governance and evaluation processes.
  • 03Robotic surgery and wearable data are key areas influencing AI usage in clinical settings.

Jul 18, 2026

Healthcare CIOs are shifting from AI deployment to AI governance

Healthcare CIOs are shifting from AI deployment to AI governance

Healthcare executives are focusing more on the governance of AI technologies rather than just their deployment. Ensuring AI models remain accurate, accountable, and trusted is becoming the new challenge for technology leaders in health systems.

  • 01AI governance is becoming more crucial than just deployment in healthcare technology.
  • 02Maintaining accuracy and accountability in AI models is a primary concern for healthcare CIOs.
  • 03Trust in AI systems is essential for their successful integration into healthcare.

Jul 18, 2026

CMS launches dedicated health technology office as AI and interoperability pressure mounts on hospital IT teams

CMS launches dedicated health technology office as AI and interoperability pressure mounts on hospital IT teams

The Centers for Medicare & Medicaid Services (CMS) have established a new Office of Health Technology and Products. This office aims to integrate AI, promote interoperability, and advance digital health strategies, thereby increasing demands on hospital IT teams.

  • 01CMS has launched an Office of Health Technology and Products to focus on AI, interoperability, and digital health strategy.
  • 02The new CMS office will increase demands and expectations on hospital IT teams.
  • 03Improving interoperability and integrating AI in healthcare is a crucial priority for CMS.

Jul 18, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512